Muscle wasting is a debilitating feature of many disease states including diabetes and renal failure. We initially identified atrogin-1 as a gene that is strongly induced during muscle wasting in various animal models of disease. Its absence protects muscles from atrophy. In the seven years since its discovery, upregulation of this gene has become a major biomarker defining the atrophy state. Atrogin-1 acts as one component of a ubiquitin-protein ligase that catalyzes the degradation of key proteins, leading to muscle wasting. During the past study period;we made large strides in understanding the signaling pathways that lead to atrogin-1 induction in atrophying muscle. Initially we had believed this gene was only expressed in skeletal and cardiac muscle, and only involved in atrophy of these tissues. Our recent data, however, has shown that atrogin-1 has more diverse cellular functions, playing a critical role in the skeletal muscle toxicity of HMG CoA reductase inhibitors (statins) and in the normal involution of the uterus following delivery. This proposal continues our exploration of atrogin-1 function by studying the pathways that induce atrogin-1 in clinically important physiological and pathological processes. We shall develop models of statin toxicity in cultured muscle cells, zebrafish and mice, and identify the signaling pathways and prenylated protein intermediates involved in atrogin-1 expression. We shall utilize our colony of atrogin-1 knockout mice to study the effects of atrogin-1 absence in the development of statin myopathy. In an effort to understand how atrogin-1 promotes protein breakdown and muscle damage, we will identify its role in the nucleus during atrophy. Elucidating the functions of atrogin-1 will help characterize the mechanisms and physiological regulation of muscle protein breakdown and may also allow the development of pharmacological inhibitors that could combat muscle wasting conditions and their associated morbidity.

Public Health Relevance

Atrogin-1 is part of a complex that triggers the destruction of muscle proteins, and its activation leads to muscle wasting. Our new data suggests that atrogin-1 has broader functions, playing a critical role in the toxicity of cholesterol-lowering medications (statins). This proposal continues our exploration of atrogin-1 function by studying the pathways that activate atrogin-1 in these conditions. These studies of atrogin-1 function will help elucidate how the body regulates muscle size, and will ultimately lead to development of drugs to combat muscle wasting.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK062307-07
Application #
7935169
Study Section
Skeletal Muscle and Exercise Physiology Study Section (SMEP)
Program Officer
Mullins, Christopher V
Project Start
2009-09-16
Project End
2011-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
7
Fiscal Year
2010
Total Cost
$331,694
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Lecker, Stewart H; Mitch, William E (2011) Proteolysis by the ubiquitin-proteasome system and kidney disease. J Am Soc Nephrol 22:821-4
Cao, Peirang; Hanai, Jun-Ichi; Tanksale, Preeti et al. (2009) Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J 23:2844-54
Menconi, Michael; Gonnella, Patricia; Petkova, Victoria et al. (2008) Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes. J Cell Biochem 105:353-64
Sacheck, Jennifer M; Hyatt, Jon-Philippe K; Raffaello, Anna et al. (2007) Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 21:140-55
Zhao, Jinghui; Brault, Jeffrey J; Schild, Andreas et al. (2007) FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 6:472-83
Bdolah, Yuval; Segal, Adam; Tanksale, Preeti et al. (2007) Atrophy-related ubiquitin ligases atrogin-1 and MuRF-1 are associated with uterine smooth muscle involution in the postpartum period. Am J Physiol Regul Integr Comp Physiol 292:R971-6
Hanai, Jun-ichi; Cao, Peirang; Tanksale, Preeti et al. (2007) The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 117:3940-51
Lecker, Stewart H; Goldberg, Alfred L; Mitch, William E (2006) Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17:1807-19
Sandri, Marco; Lin, Jiandie; Handschin, Christoph et al. (2006) PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 103:16260-5
Skurk, Carsten; Izumiya, Yasuhiro; Maatz, Henrike et al. (2005) The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 280:20814-23

Showing the most recent 10 out of 11 publications